Medtech Tariff Impact: Companies Seek Efficiency Amid Challenges

Medtech companies are still feeling the impact of tariffs imposed by the Trump administration a year ago. These tariffs target imports from key trading partners, including China and the European Union. While the goal was to boost domestic manufacturing, companies in the medtech sector are struggling to adapt. Unlike pharmaceuticals, which are investing billions in new U.S. facilities, medtech firms are not reshoring their production. Instead, they're focusing on cutting costs without raising prices for hospitals or slashing research budgets. Industry leader Glenn Hunzinger from PwC notes that these companies are looking for efficiencies to absorb the costs. Some companies face earnings impacts between $200 million and $500 million annually due to these tariffs. Interestingly, PwC estimates that medtech firms could receive up to $2.6 billion in refunds after a Supreme Court ruling questioned the legality of the tariffs. What's significant here is that the ongoing tariff challenges force medtech companies to innovate and streamline operations. This matters because, ultimately, these pressures impact the affordability of medical devices that patients rely on for their health care.